{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":1,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT02954874","nct_id":"NCT02954874","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02954874. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.","label":"Arm I (observation)","type":"EXPERIMENTAL"},{"description":"Patients receive pembrolizumab IV over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment. Patients may also undergo collection of blood samples throughout the trial.","label":"Arm II (pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08-27","type":"ESTIMATED"},"conditions":["Breast Carcinoma In Situ","Invasive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Triple-Negative Breast Carcinoma"],"enrollment":{"count":1195,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Laboratory Biomarker Analysis","type":"OTHER"},{"name":"Patient Observation","type":"OTHER"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"},{"name":"Radiation Therapy","type":"RADIATION"}],"last_update":"2026-08-31","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Invasive disease-free survival (IDFS)","timeFrame":"From date of randomization to date of first invasive recurrence, second invasive primary cancer (breast or not), or death due to any cause, assessed up to 10 years"},{"measure":"Severity of fatigue","timeFrame":"55 weeks after randomization"},{"measure":"Physical function","timeFrame":"55 weeks after randomization"}],"references":[],"start_date":{"date":"2017-01-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT02954874"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02954874"}